What are the recommended treatment options for tics, including first‑line behavioral therapy and pharmacologic medications?

Treatment of Tics

Comprehensive Behavioral Intervention for Tics (CBIT) is the first-line treatment for most individuals with bothersome tics, especially if mild to moderate in severity, with pharmacotherapy reserved for cases causing functional impairment, social problems, or when behavioral therapy is insufficient. 1, 2

Initial Management Approach

Psychoeducation and watchful waiting should be the initial step for many patients, as spontaneous remission occurs in nearly half of patients by age 18. 3, 2 Treatment is only indicated when tics cause:

• Functional impairment in daily activities 1
• Social problems or stigmatization 1
• Physical discomfort or pain 2
• Reduced quality of life 2

Behavioral Therapy (First-Line)

CBIT and Habit Reversal Training (HRT) are evidence-based behavioral interventions with high-quality data supporting their efficacy. 4, 2

• Face-to-face individual CBIT has the strongest evidence base 4
• Videoconference delivery provides similar benefit to in-person treatment 4
• Internet-based CBIT programs are more beneficial than waitlist or psychoeducation alone, though with smaller effect sizes 4
• Exposure and Response Prevention (ERP) shows equal benefit to HRT in head-to-head comparison 4

Pharmacologic Treatment (Second-Line)

When behavioral therapy is insufficient or tics are severe, pharmacotherapy should be considered. 1, 2

Alpha-2 Adrenergic Agonists (Preferred Initial Pharmacotherapy)

Clonidine and guanfacine are considered first-line pharmacologic options, particularly when comorbid ADHD or sleep disturbances are present. 3

• Clonidine dosing: Start 0.1 mg at bedtime, can increase to twice-daily dosing up to 0.4 mg/day maximum 3
• Guanfacine dosing: Weight-based at approximately 0.1 mg/kg once daily, available in 1-4 mg tablets 3
• Common adverse effects: Somnolence, fatigue, hypotension, bradycardia 3
• Administration timing: Evening dosing preferred due to sedation 3
• Onset of effect: 2-4 weeks 3

Atomoxetine (Alternative First-Line Option)

Atomoxetine is particularly useful when comorbid ADHD is present and can treat both conditions simultaneously. 3, 5

• Dosing: Up to 1.8 mg/kg or 120 mg/day maximum 3
• Onset of effect: 6-12 weeks 3
• Advantages: Does not worsen tics, "around-the-clock" effects, uncontrolled substance 3, 5
• Monitoring: Suicidality, pulse, clinical worsening 3

Dopamine Modulators (Second-Line)

Anti-dopaminergic medications (haloperidol, pimozide, risperidone, aripiprazole) should be reserved for treatment-refractory cases after failure of alpha-2 agonists and atomoxetine. 3, 1

• These agents have higher efficacy for tic reduction but greater adverse effect burden 1
• Patients must fail at least three medications including anti-dopaminergics and alpha-2 agonists before considering more invasive interventions 3

Special Considerations for Comorbid ADHD

Stimulants are the recommended first-line pharmacotherapy for ADHD symptoms in patients with tic disorders. 3, 5

• Recent double-blind studies demonstrate stimulants are highly effective for ADHD in patients with comorbid tics, and tics do not increase in the majority of patients 3
• If tics worsen on stimulants: Switch to alternative stimulant or add alpha-2 agonist 3
• Alternative approach: Use atomoxetine as monotherapy to target both ADHD and tics 5
• Augmentation strategy: Alpha-2 agonists can be added to stimulants if tics increase or used as monotherapy 5

Treatment-Refractory Cases

For severe, treatment-refractory tics in adults (>20 years old) who have failed behavioral therapy and at least three medications:

• Deep brain stimulation (DBS) may be considered 3, 6, 2
• Patients must demonstrate stable severe tics for at least 6 months independent of psychosocial stressors 3
• Yale Global Tic Severity Scale score and quality of life assessment are essential 3
• Botulinum toxin injections for focal, disabling motor tics 1

Monitoring Parameters

Regular assessment should include:

• Tic severity using standardized scales (YGTSS) 2
• Quality of life measures (GTS-QOL) 3, 7
• Comorbid psychiatric symptoms (depression, anxiety, OCD) which significantly impact both tic severity and quality of life 7
• Cardiovascular parameters (pulse, blood pressure) when using alpha-2 agonists 3

Critical Pitfalls to Avoid

• Do not delay behavioral therapy in favor of immediate pharmacotherapy for mild-moderate tics 1, 2
• Do not assume stimulants will worsen tics in ADHD patients—they are first-line treatment 3, 5
• Do not overlook comorbidities, particularly depression and ADHD, which have stronger correlation with quality of life than tic severity itself 7
• Do not use DBS in patients under age 20 due to potential for spontaneous remission 3